M.D., SVP Biomarker Data and Lab Medicine, Syapse
Biography
Dr. Anna Berry works in partnership with Syapse’s functional leaders to support product and service development, serves as a subject matter expert to Syapse’s customers, participates in joint-authored research and publications, and advances Syapse’s thought leadership efforts in the area of real-world evidence. Prior to her recent move to Syapse, she served for 6 years as the Deputy Director for Molecular Pathology and Genomics, and as the Scientific Director for the Personalized Medicine Program at the Swedish Cancer Institute in Seattle, and concurrently served as Director of Genomics Programs at CellNetix Pathology and Laboratories. Dr. Berry has focused professionally on genomics education and personalized medicine. In these roles, she has given numerous presentations, nationally and internationally, and has served on multiple task forces and committees for several professional organizations and coalitions, spanning Pathology and Oncology focused efforts.
Session Abstract – PMWC 2023 Silicon Valley
Track 2 - January 26 9.00 A.M.-4.30 P.M.
Track Chair:
- Courtney McFall, UCSF
- Ben Rubin, UCSF
Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.
Sessions:
- Clinical Studies Using RWD (PANEL)
Chair: Aaron Kamauu, Navidence
- Liora Schultz, Stanford
- Scott Morris, Optum Life Sciencess
- Sanket Dhurva, UCSF
- Motiur Rahman, FDA
- Farid Vij, Invitae - Beyond the EHR: Acquisition of RWD Types to Enable Precision Medicine (PANEL)
Chair: Riley Bove, UCSF
- Anna Berry, Sypase
- Matthew Lungren, Microsoft
- Ashley Brenton, Optum
- Vasu Chandrasekaran, Ontada - Data Linkage, Harmonization, and Quality (PANEL)
Chair: Vivek Rudrapatna, UCSF
- Rohit Vashisht, UCSF
- Adam Asare, QLHC
- Dan Riskin, Verantos
- Wanmei Ou, Ontada
- Mindy DeRouen, UCSF
- Using RWE to Uncover and Address Health Disparities (PANEL)
Chair: Chris Boone, AbbVie
- Robert Hiatt, UCSF
- Abasi Ene-Obong, 54gene
- Alice Popejoy, UC Davis Health
- Nuray Yurt, Novartis Oncology
- Vic Spain, Genentech - FDA RWD/RWE Draft and Final Guidances
- Motiur Rahman, FDA
- Fireside Chat:
- Vivek Rudrapatna, UCSF
- Hilary Marston, FDA
- Atul Butte, UCSF - From Real World to Regulatory-Grade: Navigating the Evidence Chasm
Chair: Sheila Walcoff, Goldbug Strategies
- Elaine Katrivanos, Tempus
- Kathy Hibbs, 23andMe
- Mike Ryan, McDermott Will & Emery
- Terry Myerson, Truveta
